FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897052065> ?p ?o ?g. }

• W2897052065 endingPage "423" @default.
• W2897052065 startingPage "416" @default.
• W2897052065 abstract "Background Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder characterized by circulating plasma cells and a poor prognosis. Although patients who have pPCL benefit from the use of stem cell transplantation (SCT) and novel agents, their prognosis remains inferior to that of patients who have myeloma. Methods This was a retrospective analysis of 38 consecutive patients with pPCL who were diagnosed between October 2005 and July 2016 and were registered in the Winship Cancer Institute of Emory University database. Baseline characteristics as well as data about treatment and survival outcomes were collected. Results The median patient age at diagnosis was 58 years. All patients received a bortezomib‐based induction regimen, and 92% received both bortezomib and an immunomodulatory drug (thalidomide or lenalidomide); in addition, 74% of patients underwent autologous SCT (ASCT), and 61% received maintenance therapy. The best response to first‐line therapy was a partial response or better in 87% of patients, and 45% had a complete response (CR). The achievement of ≥CR was a predictor for prolonged progression‐free survival (PFS) and overall survival (OS). The median PFS was 20 months, and the median OS was 33 months. PFS was prolonged in patients who underwent ASCT compared with those who did not undergo ASCT (25 vs 6 months; P = .004), and patients who received maintenance therapy after ASCT had prolonged median PFS (27 vs 11 months; P = .03) and a trend toward prolonged OS (median, 38 vs 22 months; P = .06) compared with those who did not receive maintenance therapy. Conclusions The current data support the use of regimens combining novel agents in the upfront treatment of patients with pPCL as well as the role of ASCT and maintenance therapy for long‐term disease control." @default.
• W2897052065 created "2018-10-26" @default.
• W2897052065 creator A5004911570 @default.
• W2897052065 creator A5007228982 @default.
• W2897052065 creator A5016626239 @default.
• W2897052065 creator A5021230077 @default.
• W2897052065 creator A5022520524 @default.
• W2897052065 creator A5023276777 @default.
• W2897052065 creator A5038076013 @default.
• W2897052065 creator A5064293376 @default.
• W2897052065 creator A5077897003 @default.
• W2897052065 creator A5087947321 @default.
• W2897052065 creator A5088696429 @default.
• W2897052065 date "2018-10-17" @default.
• W2897052065 modified "2023-10-01" @default.
• W2897052065 title "Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents" @default.
• W2897052065 cites W1529714767 @default.
• W2897052065 cites W187459702 @default.
• W2897052065 cites W1967025604 @default.
• W2897052065 cites W1970547637 @default.
• W2897052065 cites W1978930370 @default.
• W2897052065 cites W1986297232 @default.
• W2897052065 cites W2002324468 @default.
• W2897052065 cites W2003599195 @default.
• W2897052065 cites W2020298011 @default.
• W2897052065 cites W2046933119 @default.
• W2897052065 cites W2053056464 @default.
• W2897052065 cites W2054970678 @default.
• W2897052065 cites W2060957671 @default.
• W2897052065 cites W2070653024 @default.
• W2897052065 cites W2071815761 @default.
• W2897052065 cites W2099349054 @default.
• W2897052065 cites W2101761743 @default.
• W2897052065 cites W2171226089 @default.
• W2897052065 cites W2344590234 @default.
• W2897052065 cites W2549296307 @default.
• W2897052065 cites W2559471714 @default.
• W2897052065 cites W2737964630 @default.
• W2897052065 cites W2794234275 @default.
• W2897052065 cites W78262064 @default.
• W2897052065 doi "https://doi.org/10.1002/cncr.31718" @default.
• W2897052065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30332496" @default.
• W2897052065 hasPublicationYear "2018" @default.
• W2897052065 type Work @default.
• W2897052065 sameAs 2897052065 @default.
• W2897052065 citedByCount "35" @default.
• W2897052065 countsByYear W28970520652019 @default.
• W2897052065 countsByYear W28970520652020 @default.
• W2897052065 countsByYear W28970520652021 @default.
• W2897052065 countsByYear W28970520652022 @default.
• W2897052065 countsByYear W28970520652023 @default.
• W2897052065 crossrefType "journal-article" @default.
• W2897052065 hasAuthorship W2897052065A5004911570 @default.
• W2897052065 hasAuthorship W2897052065A5007228982 @default.
• W2897052065 hasAuthorship W2897052065A5016626239 @default.
• W2897052065 hasAuthorship W2897052065A5021230077 @default.
• W2897052065 hasAuthorship W2897052065A5022520524 @default.
• W2897052065 hasAuthorship W2897052065A5023276777 @default.
• W2897052065 hasAuthorship W2897052065A5038076013 @default.
• W2897052065 hasAuthorship W2897052065A5064293376 @default.
• W2897052065 hasAuthorship W2897052065A5077897003 @default.
• W2897052065 hasAuthorship W2897052065A5087947321 @default.
• W2897052065 hasAuthorship W2897052065A5088696429 @default.
• W2897052065 hasBestOaLocation W28970520651 @default.
• W2897052065 hasConcept C126322002 @default.
• W2897052065 hasConcept C141071460 @default.
• W2897052065 hasConcept C143998085 @default.
• W2897052065 hasConcept C2776063141 @default.
• W2897052065 hasConcept C2776364478 @default.
• W2897052065 hasConcept C2776694085 @default.
• W2897052065 hasConcept C2777478702 @default.
• W2897052065 hasConcept C2778283404 @default.
• W2897052065 hasConcept C2779050716 @default.
• W2897052065 hasConcept C2779609412 @default.
• W2897052065 hasConcept C2780353925 @default.
• W2897052065 hasConcept C2780739268 @default.
• W2897052065 hasConcept C2781413609 @default.
• W2897052065 hasConcept C2911091166 @default.
• W2897052065 hasConcept C71924100 @default.
• W2897052065 hasConcept C90924648 @default.
• W2897052065 hasConceptScore W2897052065C126322002 @default.
• W2897052065 hasConceptScore W2897052065C141071460 @default.
• W2897052065 hasConceptScore W2897052065C143998085 @default.
• W2897052065 hasConceptScore W2897052065C2776063141 @default.
• W2897052065 hasConceptScore W2897052065C2776364478 @default.
• W2897052065 hasConceptScore W2897052065C2776694085 @default.
• W2897052065 hasConceptScore W2897052065C2777478702 @default.
• W2897052065 hasConceptScore W2897052065C2778283404 @default.
• W2897052065 hasConceptScore W2897052065C2779050716 @default.
• W2897052065 hasConceptScore W2897052065C2779609412 @default.
• W2897052065 hasConceptScore W2897052065C2780353925 @default.
• W2897052065 hasConceptScore W2897052065C2780739268 @default.
• W2897052065 hasConceptScore W2897052065C2781413609 @default.
• W2897052065 hasConceptScore W2897052065C2911091166 @default.
• W2897052065 hasConceptScore W2897052065C71924100 @default.
• W2897052065 hasConceptScore W2897052065C90924648 @default.
• W2897052065 hasIssue "3" @default.
• W2897052065 hasLocation W28970520651 @default.

• next